Personalized immune cells take aim at Drug-Resistant eye virus
NCT ID NCT07679412
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests a new treatment called LB-DTK-CMV for people with cytomegalovirus (CMV) retinitis that has not responded to standard antiviral medicines. The treatment uses a patient's own immune cells, specially trained to attack CMV, and is given as two infusions. The trial aims to see if this approach is safe and can reduce the virus in the eye and blood, as well as improve vision-related symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LB-DTK-CMV (a personalized T-cell therapy made from the patient's own immune cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with CMV retinitis that does not respond to standard antiviral drugs.
- What could go wrong
- This is a very early, small study with only 5 participants, so results may not apply to everyone. The therapy involves infusions that could cause side effects or fail to control the infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV RETINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Catholic University of Korea Seoul St.Mary's Hospital
RECRUITINGSeoul, 06591, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.